Monash University-led research is using maths to predict how new combination therapies can help patients with breast cancer who no longer respond to conventional therapies.
Published in NPJ Precision Oncology, the Monash Biomedicine Discovery Institute (BDI) study investigated breast cancer driven by a specific protein, PI3K, and how new combination therapies could effectively shut it down.
Co-senior author Associate Professor Lan Nguyen said: “We have created new computational models that mimic the behaviour of the cancer-promoting protein PI3K and its extensive downstream targets. This is critical because the PI3K pathway is mutated in about 30 per cent of breast cancer patients, and contributes to resistance to primary anti-cancer treatments.
“Using this mathematical approach, we have predicted new combination therapies and confirmed through experiments in the lab that these new combination treatments are more effective at combating PI3K-mutant breast cancer cells than targeting PI3K alone.”
Co-senior author Dr Antonella Papa said the study was an important step forward in understanding and overcoming breast cancer drug resistance using innovative predictive models.
“Our study has found the way in which breast cancer cells become resistant to alpelisib, a PI3K inhibitor used in the clinic for the treatment of PI3K-mutant breast cancer,” she said. “Using this knowledge, we have identified additional proteins that when inhibited, restore sensitivity to alpelisib and halt the proliferation of resistant cells.”
Associate Professor Nguyen emphasised the formidable challenge of drug resistance in cancer treatment.
“Our study not only sheds light on the complex mechanisms causing therapeutic resistance to alpelisib, but also provides a computational approach for systematically prioritising combination therapies in an unbiased manner,” he said. “This could accelerate the discovery of effective treatments, making it a valuable framework for future research in oncology and beyond.
“As drug resistance is a common reason for treatment failure, our research could lead to the testing and approval of new therapies that maintain their effectiveness longer, potentially improving survival rates and quality of life for patients. In the future, this could also mean fewer side effects and more personalised treatment options."
Associate Professor Nguyen said the next steps would entail rigorous preclinical evaluation of the identified drug combinations. “Following successful preclinical studies, initiating clinical trials will be essential to confirm the safety and efficacy of these new combination therapies in humans,” he said.
Dr Papa said: “Previous studies have demonstrated that similar treatments effectively reduce tumour growth using the mouse as a preclinical model. If preclinical validation progresses further, initial clinical trials could commence within a few years. Continuous collaboration between us researchers, clinicians, and regulatory bodies will be key to accelerating this process,” she said.
The authors acknowledged the study was a team-effort between two laboratories within the Monash BDI, and the collaborative nature of the work had been instrumental in achieving these results. “It highlights the power of interdisciplinary approaches in addressing complex medical challenges like cancer,” they said.
Read the full paper published in Nature NPJ Precision Oncology, ‘Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer’.
DOI: 10.1038/s41698-024-00496-y
MEDIA ENQUIRIES
Monash Media
Cheryl Critchley, Media Manager, Monash University
E: [email protected]
M: +61 (0)418 312 596
E: [email protected]
T: +61 (0) 3 9903 4840
For more Monash media stories, visit our news and events
About the Monash Biomedicine Discovery Institute
Committed to making the discoveries that will relieve the future burden of disease, the Monash Biomedicine Discovery Institute (BDI) at Monash University brings together more than 120 internationally-renowned research teams. Spanning seven discovery programs across Cancer, Cardiovascular Disease, Development and Stem Cells, Infection, Immunity, Metabolism, Diabetes and Obesity, and Neuroscience, Monash BDI is one of the largest biomedical research institutes in Australia. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.